← All trials
NCT05516316
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2022
- Primary completion
- May 31, 2023
- Completion date
- May 31, 2023
- First posted
- Aug 25, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 48
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- EpiEndo PharmaceuticalsLead sponsor
- FGK Clinical Research GmbHCollaborator
- University of California, IrvineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.